Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M. Takigawa K, et al. Among authors: mizoguchi m. J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28. J Neurooncol. 2021. PMID: 34322829 Free PMC article.
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K. Hata N, et al. Among authors: mizoguchi m. J Neurooncol. 2020 Feb;146(3):451-458. doi: 10.1007/s11060-019-03339-0. Epub 2020 Feb 4. J Neurooncol. 2020. PMID: 32020475
Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y, Michiwaki Y, Amemiya T, Takigawa K, Funakoshi Y, Sako A, Iwaki T, Iihara K, Mizoguchi M. Fujioka Y, et al. Among authors: mizoguchi m. J Neurooncol. 2021 Mar;152(1):47-54. doi: 10.1007/s11060-020-03682-7. Epub 2021 Jan 8. J Neurooncol. 2021. PMID: 33417137 Free PMC article.
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M. Funakoshi Y, et al. Among authors: mizoguchi m. Cancer Med. 2021 May;10(10):3177-3187. doi: 10.1002/cam4.3860. Epub 2021 Apr 10. Cancer Med. 2021. PMID: 33838014 Free PMC article.
Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma).
Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Yoshimoto K, Mizoguchi M, Iihara K. Funakoshi Y, et al. Among authors: mizoguchi m. Int J Clin Oncol. 2021 Aug;26(8):1441-1449. doi: 10.1007/s10147-021-01929-5. Epub 2021 May 11. Int J Clin Oncol. 2021. PMID: 33974184 Free PMC article.
Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.
Funakoshi Y, Takigawa K, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Otsuji R, Sako A, Yoshitake T, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Yoshimoto K. Funakoshi Y, et al. Among authors: mizoguchi m. World Neurosurg. 2022 Mar;159:e479-e487. doi: 10.1016/j.wneu.2021.12.075. Epub 2021 Dec 25. World Neurosurg. 2022. PMID: 34958993
493 results